Clinical pharmacokinetics and pharmacodynamics of colistin

N Grégoire, V Aranzana-Climent, S Magréault… - Clinical …, 2017 - Springer
In this review, we provide an updated summary on colistin pharmacokinetics and
pharmacodynamics. Colistin is an old molecule that is frequently used as last-line treatment …

[HTML][HTML] Systematic Review of Antimicrobial Combination Options for Pandrug-Resistant Acinetobacter baumannii

S Karakonstantis, P Ioannou, G Samonis, DP Kofteridis - Antibiotics, 2021 - mdpi.com
Antimicrobial combinations are at the moment the only potential treatment option for
pandrug-resistant A. baumannii. A systematic review was conducted in PubMed and Scopus …

[HTML][HTML] An overview of antimicrobial resistance in Saudi Arabia (2013–2023) and the need for national surveillance

AK Thabit, AY Alabbasi, FS Alnezary, IA Almasoudi - Microorganisms, 2023 - mdpi.com
Antimicrobial resistance (AMR) is a well-recognized global threat. The World Health
Organization (WHO) issued a report ranking the critical types of bacterial resistance that …

[HTML][HTML] An update on technical, interpretative and clinical relevance of antimicrobial synergy testing methodologies

S Laishram, AK Pragasam, YD Bakthavatchalam… - Indian Journal of …, 2017 - Elsevier
Testing for antimicrobial interactions has gained popularity in the last decade due to the
increasing prevalence of drug-resistant organisms and limited options for the treatment of …

[HTML][HTML] Emerging status of multidrug-resistant bacteria and fungi in the arabian peninsula

JF Borgio, AS Rasdan, B Sonbol, G Alhamid… - Biology, 2021 - mdpi.com
Simple Summary The incidence and developing status of multidrug-resistant bacteria and
fungi, as well as their related mortality, is reviewed by a systematic published literature …

In search for a synergistic combination against pandrug-resistant A. baumannii; methodological considerations

S Karakonstantis, P Ioannou, DD Kofteridis - Infection, 2022 - Springer
Purpose Pending approval of new antimicrobials, synergistic combinations are the only
treatment option against pandrug-resistant A. baumannii (PDRAB). Considering the lack of a …

[HTML][HTML] Multidrug resistance Acinetobacter species at the intensive care unit, Aseer Central Hospital, Saudi Arabia: A one year analysis

A Al Bshabshe, MRP Joseph, A Al Hussein… - Asian Pacific journal of …, 2016 - Elsevier
Objective To identify and to determine the antimicrobial susceptibility of Acinetobacter
baumannii (A. baumannii) clinical isolates from ICU at Aseer Central Hospital. Methods The …

[HTML][HTML] Therapeutic drug monitoring-guided high dose meropenem therapy of a multidrug resistant Acinetobacter baumannii-A case report

U Liebchen, M Paal, J Jung, I Schroeder, L Frey… - … medicine case reports, 2020 - Elsevier
Background Infections with multidrug resistant Acinetobacter baumannii in
immunocompromised patients are life-threatening. Therapeutic options are rare in this …

Multidrug-resistant Acinetobacter baumannii infections: Current evidence on treatment options and the role of pharmacokinetics/pharmacodynamics in dose …

SMS Lim, FB Sime, JA Roberts - International journal of antimicrobial …, 2019 - Elsevier
Acinetobacter baumannii remains a difficult-to-treat pathogen that poses a significant
challenge to clinicians and costs to the healthcare system. There is a lack of clinical efficacy …

Synergy effect of meropenem-based combinations against Acinetobacter baumannii: A systematic review and meta-analysis

Z Jiang, X He, J Li - Infection and drug resistance, 2018 - Taylor & Francis
Purpose: The main objective of our meta-analysis was to examine the in vitro synergistic
effect of meropenem-based combination therapies against Acinetobacter baumannii through …